Kura Oncology, Inc.
(NASDAQ : KURA)

( )
KURA PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Major
symbolcompany%chnglast%shortavg$volume
JNJJohnson & Johnson -2.81%177.010.7%$1390.13m
MRKMerck & Co., Inc. -2.60%91.960.7%$1216.80m
PFEPfizer Inc. -2.29%50.690.9%$1177.94m
BMYBristol-Myers Squibb Co. -1.58%78.721.0%$1104.13m
LLYEli Lilly & Co. -2.91%317.751.1%$1091.72m
ABBVAbbVie, Inc. -0.40%152.531.9%$989.13m
AZNAstraZeneca Plc -0.87%65.931.0%$446.77m
SGENSeagen Inc. 0.42%178.475.7%$327.62m
TPTXTurning Point Therapeutics, Inc. -0.28%75.060.0%$295.90m
GSKGSK Plc -0.78%43.360.2%$285.09m
HZNPHorizon Therapeutics Plc -4.45%81.695.4%$176.63m
NVSNovartis AG -1.27%84.200.2%$166.38m
MRTXMirati Therapeutics, Inc. -1.67%68.501.6%$162.75m
NVONovo Nordisk A/S -4.04%108.330.1%$145.58m
BHVNBiohaven Pharmaceutical Holding Co. Ltd. 0.47%144.690.0%$142.13m

Company Profile

Kura Oncology, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the research and development of medicines for the treatment of cancer. Its pipeline includes Tipifarnib, which is a Farnesyl transferase inhibitor for HRAS Mutant Solid Tumors, Chronic Myelomonocytic Leukemia, KO-947, which is an ERK inhibitor for MAPK Pathway Tumors, and KO-539, which is a Menin MLL inhibitor for acute leukemias. The company was founded by Troy E. Wilson, Yi Liu, Pingda Ren and Antonio Gualberto on August 22, 2014 and is headquartered in San Diego, CA.